Next-Generation Sequencing and Clinical Outcomes of Patients With Lung Adenocarcinoma Treated With Stereotactic Body Radiotherapy

作者：Cassidy Richard J; Zhang Xinyan; Patel Pretesh R; Shelton Joseph W; Escott Chase E; Sica Gabriel L; Rossi Michael R; Hill Charles E; Steuer Conor E; Pillai Rathi N; Ramalingam Suresh S; Owonikoko Taofeek K; Behera Madhusmita; Force Seth D; Fernandez Felix G; Curran Walter J; Higgins Kristin A

来源：Cancer, 2017, 123(19): 3681-3690.

DOI：10.1002/cncr.30794

• lung adenocarcinomas
• lung mutations
• next-generation sequencing
• stereotactic body radiotherapy
• targeted therapy

BACKGROUND: Genetic aberrations are well characterized in lung adenocarcinomas (LACs) and clinical outcomes have been influenced by targeted therapies in the advanced setting. Stereotactic body radiotherapy (SBRT) is the standard-of-care therapy for patients with nonoperable, early-stage LAC, but to the authors' knowledge, no information is available regarding the impact of genomic changes in these patients. The current study sought to determine the frequency and clinical impact of genetic aberrations in this population. METHODS: Under an Institutional Review Board- approved protocol, the records of 242 consecutive patients with earlystage lung cancers were reviewed; inclusion criteria included LAC histology with an adequate tumor sample for the successful use of next-generation sequencing and fluorescence in situ hybridization testing. Univariate analysis was performed to identify factors associated with clinical outcomes. RESULTS: LAC samples from 98 of the 242 patients were reviewed (40.5%), of whom 45 patients (46.0%) had genetic testing. The following mutations were noted: KRAS in 20.0% of samples, BRAF in 2.2% of samples, SMAD family member 4 (SMAD4) in 4.4% of samples, epidermal growth factor receptor (EGFR) in 15.6% of samples, STK1 in 2.2% of samples, tumor protein 53 (TP53) in 15.6% of samples, and phosphatase and tensin homolog (PTEN) in 2.2% of samples. The following gene rearrangements were observed: anaplastic lymphoma kinase (ALK) in 8.9% of samples, RET in 2.2% of samples, and MET amplification in 17.8% of samples. The median total delivered SBRT dose was 50 grays (range, 48-60 grays) over a median of 5 fractions (range, 38 fractions). The KRAS mutation was associated with worse local control (odds ratio [OR], 3.64; P <. 05). MET amplification was associated with worse regional (OR, 4.64; P <. 05) and distant (OR, 3.73; P <. 05) disease control. CONCLUSIONS: To the authors' knowledge, the current series is the first to quantify genetic mutations and their association with clinical outcomes in patients with early-stage LAC treated with SBRT. KRAS mutations were associated with worse local control and MET amplification was associated with worse regional and distant disease control, findings that need to be validated in a prospective setting.

• 出版日期2017-10-1